May 23, 2017

1 Min Read
Granules India to Invest $35M in U.S. Manufacturing Site
The Granules Pharmaceuticals site in Chantilly, VA. Image courtesy of Granules India

Hyderabad, India-based global pharmaceutical manufacturing firm Granules India Ltd. to expand the R&D and production capabilities of its Chantilly, VA manufacturing facility with an investment of $35 million in its American subsidiary, Granules Pharmaceuticals Inc., Virginia Governor Terry McAuliffe Authority announced by press release Monday.

“We are very excited about our plans for expansion in Fairfax County. There is a lot of untapped potential with a highly educated and technically savvy workforce, reliable security, diverse amenities, and state-of-the-art infrastructure including Dulles International Airport, the Port of Virginia, and the expanded Metrorail in close proximity,” said Priyanka Chigurupati, executive vice president of Granules India, in a statement.

Currently Granules Pharmaceuticals uses the 100,000-sq-ft Chantilly site to research and develop product formulations. 50,000 sq ft will be added over two years allowing the firm to manufacture finished dose products, FiercePharma reported.

The company said 102 jobs will be created at the facility as a result of the expansion project.

Granules India and its subsidiaries manufacture active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages. 

For more articles, news, and equipment reviews, visit our Equipment Zones

Sign up for the Powder & Bulk Solids Weekly newsletter.

You May Also Like